Neurotherapeutics, the official journal of the American Society for Experimental Neurotherapeutics, has gone through major growth and transformation since its launch in 2004. It began as a review journal, with each issue consisting of invited critical reviews that focus on a theme related to advancing therapeutics for neurological disorders. In 2011, the Journal began publishing unsolicited original research articles relevant to its mission in addition to the thematic reviews.
Since I assumed the role of Editor-in-Chief in 2014, the number of manuscript submissions has more than tripled, and the number of published research articles has quadrupled. In 2016, we also added the new feature of Current Perspectives to each issue. These invited manuscripts provide a platform for publishing points-of-view by key opinion leaders on current hot topics in neurologic therapeutics.
This growth has necessitated expanding the editorial leadership team. I would like to take this opportunity to express my gratitude to members of our Editorial Board and external peer reviewers who are critical for maintaining the highest quality of publications. Thanks also to our Editorial Manager Linda Powell who continues to run the editorial office and ensures efficient handling of Journal tasks. In addition, our ongoing partnership with the production staff at Springer Nature allows for an effective collaboration to publish each issue of Neurotherapeutics.
As the current trajectory of growth continues, my colleagues on the editorial team and I look forward to maintaining rigorous peer review standards and publishing the latest research discoveries and authoritative reviews of broad interest on current and emerging treatments of neurological disorders.
M. Maral Mouradian, MD Editor-in-Chief
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